By 2030, the Saudi Arabia infectious disease therapeutics market is anticipated to reach a value of $3.21 Bn from $2.04 Bn in 2022, growing at a CAGR of 5.9% during 2022-30. The Infectious Disease Therapeutics in Saudi Arabia is dominated by a few domestic pharmaceutical companies such as SPIMACO, Tabuk Pharmaceuticals, and Taibah Valley. The Infectious Disease Therapeutics market in Saudi Arabia is segmented into different therapeutic areas and different disease types. The major factors affecting the Saudi Arabia infectious disease therapeutics market are the increasing disease burden of communicable diseases like TB, hepatitis, and COVID-19 and the healthcare funding for infectious disease treatment in various areas of Saudi Arabia.
By 2030, the Saudi Arabia infectious disease therapeutics market is anticipated to reach a value of $3.21 Bn from $2.04 Bn in 2022, growing at a CAGR of 5.9% during 2022-30.
Saudi Arabia is a high-income, developing country in the Middle East bordering the Persian Gulf and the Red Sea. Lower respiratory infections are one of the top five causes of death in Saudi Arabia, according to the CDC. Pharmaceutical firms such as Pfizer, Novartis, and Sanofi, as well as diagnostic businesses such as Roche and Abbott Laboratories, are among the leading competitors in the Saudi infectious disease industry.
In terms of drug consumption, Saudi Arabia has a large and growing pharmaceutical market. According to a report by the Saudi Food and Drug Authority, the Saudi Arabian pharmaceutical market was valued at approximately $8.6 Bn in 2019, with drugs for infectious diseases being one of the largest therapeutic categories. Saudi Arabia's government spends 5.5% of its GDP on healthcare.
Market Growth Drivers Analysis
Saudi Arabia is also involved in vaccine development, with the Ministry of Health in charge of vaccine development and delivery. The ministry manufactures vaccinations for a variety of diseases, including influenza, meningococcal illness, and hepatitis B. Middle East Respiratory Syndrome (MERS) is a novel viral respiratory infection in humans. Saudi Arabia was the first to report on it. Economic diversification and reform efforts to attract foreign investment are critical factors to consider while doing business in Saudi Arabia. These aspects could boost Saudi Arabia's infectious disease therapeutics market.
Market Restraints
Developing new pharmaceuticals and treatments necessitates adhering to regulatory rules established by authorities such as the Saudi Food and Drug Authority (SFDA) in Saudi Arabia. These requirements can be complicated and time-consuming, resulting in delays and higher expenses. Some viral diseases may be stigmatised or connected with specific cultural or societal behaviours, which can limit demand for novel therapies or make research in this field difficult. The danger to business is increased by Saudi Arabia's fragility in the non-oil sector, which is worsened by COVID-19. It is also reliant on foreign labour. These factors may deter new entrants into the Saudi Arabia infectious disease therapeutics market.
Key Players
January 2022: Saudi Pharmaceutical Industries and Medical Appliances Corp. (SPIMACO) struck an eight-year agreement with the Swiss company VIFOR PHARMA. The agreement is part of SPIMACO's strategic business plan, which aims to expand, spread, and diversify by entering domains to achieve the highest levels of healthcare, meet Saudi market needs, and ensure the continuity of medication available to patients in accordance with internationally recognised specifications and standards.
The Saudi Food and Drug Authority oversees regulating infectious illness medicines in Saudi Arabia (SFDA). The SFDA oversees assessing the safety, efficacy, and quality of all medications and medical equipment, including those used to treat infectious diseases. The Ministry of Health (MOH) oversees the healthcare system and offers a variety of services, including medicines and treatments for infectious diseases.
1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
By Mode of Treatment (Revenue, USD Billion):
By Applications (Revenue, USD Billion):
By Disease Type (Revenue, USD Billion):
By Target Organism (Revenue, USD Billion):
By End User (Revenue, USD Billion):
Methodology for Database Creation
Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.
Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.
How Do We Get It?
Our database is created and maintained through a combination of secondary and primary research methodologies.
1. Secondary Research
With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:
With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:
2. Primary Research
To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:
Combining Secondary and Primary Research
By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:
Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.
By 2030, it is anticipated that the Saudi Arabia infectious disease therapeutics market will reach a value of $3.21 Bn from $2.04 Bn in 2022, growing at a CAGR of 5.9% during 2022-2030.
In Saudi Arabia, the regulation of infectious disease therapeutics is overseen by the Saudi Food and Drug Authority (SFDA) and the Ministry of Health (MOH).
The Infectious Disease Therapeutics in Saudi Arabia is dominated by a few domestic pharmaceutical companies such as SPIMACO, Tabuk Pharmaceuticals and Taibah Valley.